Company: LIMN
Filing Date: 2025-05-06
Form Type: 8-K
Source: 0001104659-25-045127
Chunk: 2

Company: Liminatus Pharma, Inc.
Filing Date: 2025-05-06
Form: 8-K
Item: Item 3.03
Chunk 2
---
Item 3.03. Material Modification to Rights
of Security Holders.

At the Special Meeting, Iris
stockholders approved the Company’s amended and restated certificate of incorporation (the “ Charter”) to, among other
things, change the corporate name from “ Iris Acquisition Corp” to “ Iris Parent Holding Corp.,” change the total
number of shares of the Company’s capital stock from (a) 280,000,000 Iris Class A Shares, 20,000,000 shares of Class B
Common Stock and 1,000,000 shares of preferred stock, par value $0.0001 per share, of Iris to (b) 500,000,000 shares of ParentCo
Common Stock and 1,000,000 shares of preferred stock, par value $0.0001 per share, of ParentCo, eliminate the Class B Common Stock
and any rights of holders thereof and authorize all other changes in connection with the replacement of Iris’s constitutional documents
with the Charter and the Company’s amended and restated bylaws (the “ Bylaws”) in connection with the consummation of
the Business Combination. The terms of the Charter are described in greater detail in the section titled “ The ParentCo Charter
Proposal” beginning on page 131 of the Proxy Statement/Prospectus and is incorporated herein by reference. The Charter,
which became effective upon filing with the Secretary of State of the State of Delaware on the Closing Date, includes the amendments proposed
by the ParentCo Charter Proposal.

The description of the Charter
and the general effect of the Charter and the Bylaws upon the rights of holders of the Company’s capital stock are included in the
Proxy Statement/Prospectus under the sections titled (i) “ The Advisory Charter Proposals” beginning on page 133
of the Proxy Statement/Prospectus, (ii) “ Comparison of Stockholders’ Rights” beginning on page 148 of the
Proxy Statement/Prospectus, and (iii) “ Description of ParentCo Capital Stock” beginning on page 214 of the Proxy
Statement/Prospectus, which are incorporated herein by reference.

On April 30, 2025, in
connection with the Business Combination, the Company filed the Charter with the Secretary of State of the State of Delaware, including
the changing of the Company’s name to “ Liminatus Pharma, Inc.,” and adopted the Bylaws, in the form attached as
Annex I to the Proxy Statement/